NZ776807A - Antibody that binds to vegf and il-1beta and methods of use - Google Patents

Antibody that binds to vegf and il-1beta and methods of use

Info

Publication number
NZ776807A
NZ776807A NZ776807A NZ77680719A NZ776807A NZ 776807 A NZ776807 A NZ 776807A NZ 776807 A NZ776807 A NZ 776807A NZ 77680719 A NZ77680719 A NZ 77680719A NZ 776807 A NZ776807 A NZ 776807A
Authority
NZ
New Zealand
Prior art keywords
antibody
1beta
cdr
human
vegf
Prior art date
Application number
NZ776807A
Other versions
NZ776807B2 (en
Inventor
Joerg Benz
Hubert Kettenberger
Stefan Lorenz
Roland Beckmann
Christian Gassner
Guido Hartmann
Peter Michael Huelsmann
Kristian Hobolt Jensen
Olaf Mundigl
Stefan Dengl
Sabine Imhof-Jung
Joerg Moelleken
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NZ776807A publication Critical patent/NZ776807A/en
Publication of NZ776807B2 publication Critical patent/NZ776807B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.

Claims (16)

PATENT CLAIMS
1. An antibody that binds to human VEGF and to human IL-1beta, comprising a 5 VH sequence of SEQ ID NO:11 and a VL sequence of SEQ ID NO:12.
2. The antibody of claim 1, wherein the antibody comprises a VEGF paratope and an IL-1beta paratope within one cognate pair of a variable light chain domain (VL domain) and a variable heavy chain domain (VH domain), wherein the 10 VEGF paratope comprises amino acid residues from CDR-H2, CDR-L1 and CDR-L3 of the antibody, and wherein the IL-1beta paratope comprises amino acid residues from the CDR-H1, CDR-H3 and CDR-L2 of the antibody.
3. The antibody of any one of the preceding claims comprising a heavy chain amino 15 acid sequence of SEQ ID NO:20 and a light chain amino acid sequence of SEQ ID NO:19.
4. The antibody of any one of the preceding claims, wherein an antibody Fab fragment of the antibody binds (i) to human VEGF121 with a K of less than 10 20 pM as measured by surface plasmon resonance, and (ii) to human IL-1beta with a K of less than 30 pM as measured by surface plasmon resonance.
5. The antibody of any one of the preceding claims, wherein an antibody Fab fragment of the antibody exhibits an aggregation onset temperature of more than 25 70 °C.
6. The antibody of any one of the preceding claims, wherein an antibody Fab fragment of the antibody exhibits a melting temperature of more than 80 °C as measured by dynamic light scattering.
7. The antibody of any one of the preceding claims, wherein the antibody is a bispecific antibody or binding fragment thereof.
8. An isolated nucleic acid encoding the antibody of any one of claims 1 to 7.
9. An isolated host cell comprising the nucleic acid of claim 8.
10. An expression vector comprising the nucleic acid of claim 8.
11. A method of producing an antibody that binds to human VEGF and to human IL- 1beta comprising culturing the host cell of claim 9 so that the antibody is produced.
12. The antibody of any one of claims 1-7 substantially as herein described and with reference to any example thereof and with or without reference to the figures. 10
13. The nucleic acid of claim 8 substantially as herein described and with reference to any example thereof and with or without reference to the figures.
14. The host cell of claim 9 substantially as herein described and with reference to any example thereof and with or without reference to the figures.
15. The vector of claim 10 substantially as herein described and with reference to any example thereof and with or without reference to the figures.
16. The method of claim 11 substantially as herein described and with reference to 20 any example thereof and with or without reference to the figures. 1 / 12
NZ776807A 2019-12-20 Antibody that binds to vegf and il-1beta and methods of use NZ776807B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18215023 2018-12-21
PCT/EP2019/086529 WO2020127873A1 (en) 2018-12-21 2019-12-20 Antibody that binds to vegf and il-1beta and methods of use

Publications (2)

Publication Number Publication Date
NZ776807A true NZ776807A (en) 2025-05-02
NZ776807B2 NZ776807B2 (en) 2025-08-05

Family

ID=

Also Published As

Publication number Publication date
JP2023162345A (en) 2023-11-08
CN113195531A (en) 2021-07-30
BR112021012022A2 (en) 2021-11-03
AR117468A1 (en) 2021-08-11
EP3898671A1 (en) 2021-10-27
CA3123503A1 (en) 2020-06-25
KR20210099053A (en) 2021-08-11
MX2021007421A (en) 2021-08-05
JP7114813B2 (en) 2022-08-08
CO2021008755A2 (en) 2021-07-19
CN119708249A (en) 2025-03-28
JP2022508393A (en) 2022-01-19
MY199149A (en) 2023-10-18
IL283566A (en) 2021-07-29
JP7342212B2 (en) 2023-09-11
AU2019406712A1 (en) 2021-06-17
CN119751690A (en) 2025-04-04
KR20240042566A (en) 2024-04-02
PE20211294A1 (en) 2021-07-20
WO2020127873A1 (en) 2020-06-25
JP7680504B2 (en) 2025-05-20
PH12021551470A1 (en) 2022-04-11
KR102652720B1 (en) 2024-03-29
CR20210332A (en) 2021-09-09
CN119708247A (en) 2025-03-28
US11866490B2 (en) 2024-01-09
TW202039552A (en) 2020-11-01
CL2021001616A1 (en) 2022-01-14
US20220041707A1 (en) 2022-02-10
US11130804B2 (en) 2021-09-28
CN113195531B (en) 2025-03-04
JP2022141933A (en) 2022-09-29
TWI921882B (en) 2026-04-11
ZA202103643B (en) 2022-09-28
TW202515909A (en) 2025-04-16
TWI853867B (en) 2024-09-01
AU2019406712B2 (en) 2024-08-22
SG11202106198YA (en) 2021-07-29
US20200199214A1 (en) 2020-06-25
CN119708248A (en) 2025-03-28
CN119708246A (en) 2025-03-28
JP2025121995A (en) 2025-08-20
US20240101657A1 (en) 2024-03-28
UA129264C2 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
JP2018520657A5 (en)
JP2020536543A5 (en)
HRP20190932T1 (en) Antibody molecules which bind il-17a and il-17f
US20220403028A1 (en) Novel anti-cd3 antibodies
AR126758A2 (en) ANTI-LY6G6D ANTIBODIES AND METHODS OF USE
JP2012525829A5 (en)
PE20121646A1 (en) ANTI-TSLP ANTIBODY MODIFIED BY GENETIC ENGINEERING TECHNIQUES
HRP20191697T1 (en) Binding molecules for bcma and cd3
GB2595379A (en) Anti-BTLA antibodies
RU2012147286A (en) HUMANIZED ANTIBODIES TO FACTOR D AND THEIR APPLICATIONS
FI3322727T3 (en) Humanized or chimeric CD3 antibodies
JP2017505125A5 (en)
CR20240482A (en) Anti-tl1a antibodies and methods of use thereof
JP2022514734A5 (en)
WO2022157773A2 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
JP2020532572A5 (en)
JP2023549555A5 (en)
AU2019263850A1 (en) High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
AR126009A1 (en) CD28 ANTIGEN-BINDING AGONIST MOLECULES THAT TARGET EPCAM
JP2022501065A5 (en)
FI4031569T3 (en) STEM CELL FACTOR ANTIBODIES AND METHODS OF USING THEM
JP2022523145A5 (en)
PE20212269A1 (en) ANTI-TREM1 ANTIBODIES AND RELATED METHODS
JP7652705B2 (en) Antibodies with specificity for BTN2 and uses thereof
NZ776807B2 (en) Antibody that binds to vegf and il-1beta and methods of use

Legal Events

Date Code Title Description
PSEA Patent sealed